Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 3;14(1):325-334.
doi: 10.21037/qims-23-702. Epub 2023 Nov 30.

Prognostic value of 18F-FDG PET/CT tumor metabolic parameters and Ki-67 in pre-treatment diffuse large B-cell lymphoma

Huixia Geng  1   2 , Ke Lian  2   3 , Wanchun Zhang  1   2
Affiliations

Prognostic value of 18F-FDG PET/CT tumor metabolic parameters and Ki-67 in pre-treatment diffuse large B-cell lymphoma

Huixia Geng et al. Quant Imaging Med Surg. .

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive lymphoma. Rituximab-based conventional chemotherapy still leads to drug resistance or relapse in 30-40% of patients. Therefore, early identification of high-risk patients and accurate assessment of prognosis are very important for clinical decision-making. The aim of this study is to investigate the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) of tumor metabolic, clinical and biological parameters in the prognostic risk stratification of DLBCL before treatment.

Methods: We retrospectively collected clinical data on 63 patients with newly diagnosed DLBCL admitted to Shanxi Bethune Hospital during the period from November 2016 to April 2020 who underwent 18F-FDG PET/CT prior to treatment in a cohort study. Metabolic, clinical, and biological parameters were analyzed by Cox regression. Kaplan-Meier curves of patient survival were compared by the log-rank test.

Results: The median follow-up was 21 months. The 2-year progression-free survival (PFS) was 47.62%, and the overall survival (OS) was 53.97%. The subtype, double expression, Ann Abor stage, NCCN-IPI score, Ki-67, maximum standardized uptake value (SUVmax), bulk volume glycolysis (BVG), total lesion glycolysis (TLG), total metabolic tumor volume (TMTV) were the influencing factors for PFS and OS (P<0.050) in univariate analysis. BVG (PFS: HR =6.62, P<0.001; OS: HR =3.53, P=0.029), TLG (PFS: HR =8.56, P<0.001; OS: HR =5.20, P=0.004), TMTV (PFS: HR =12.02, P=0.001; OS: HR =5.05, P=0.033) and Ki-67 were found to be independent prognostic risk stratification parameters affecting PFS and OS by multivariate regression analysis. The 2-year PFS and OS rates for patients with high BVG (≥288.00 cm3), TLG (≥1,854.00 cm3), TMTV (≥103.00 cm3), and Ki-67 (≥85%) were 20% and 28.57%, 9.68% and 22.58%, 20.51%, and 30.77%, and 25% and 33.33%, respectively; and the 2-year PFS and OS rates for patients with low BVG (<288.00 cm3), TLG (<1,854.00 cm3), TMTV (<103.00 cm3), and Ki-67 (<85%) patients were 82.14% and 85.71%, 84.37% and 84.37%, 91.67% and 91.67%, and 61.54% and 66.67%, respectively. Patients with high BVG, TLG, TMTV, and Ki-67 had a worse 2-year PFS as well as OS rate (Ki-67: P=0.0018/P=0.0025; P<0.0001 for the rest of the groups).

Conclusions: Our findings suggest that BVG, TLG, TMTV, and Ki-67 are independent prognostic indicators for survival in patients with pre-treatment DLBCL, especially BVG, which is a novel prognostic indicator that has to be validated in future research.

Keywords: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT); Diffuse large B-cell lymphoma (DLBCL); prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-23-702/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of patient selection.
Figure 2
Figure 2
Kaplan-Meier curves for PFS and OS based on BVG, TLG, TMTV and Ki-67 in all patients. (A) PFS in relation to BVG; (B) OS in relation to BVG; (C) PFS in relation to TLG; (D) OS in relation to TLG; (E) PFS in relation to TMTV; (F) OS in relation to TMTV; (G) PFS in relation to Ki-67; (H) OS in relation to Ki-67. PFS, progression-free survival; OS, overall survival; BVG, bulk volume glycolysis; TLG, total lesion glycolysis; TMTV, total metabolic tumor volume.
See this image and copyright information in PMC

References

    1. Jiang J, Lyu W, Chen N. A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020. Comput Biol Med 2022;146:105565. 10.1016/j.compbiomed.2022.105565 - DOI - PubMed
    1. Wang J, Zhang R, Ding X, Jin Y, Qin R, Xia B, Liao Q, Hu H, Song W, Wang Z, Zhang X, Xu J. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient. Immunotherapy 2022;14:599-607. 10.2217/imt-2021-0247 - DOI - PubMed
    1. He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia 2021;35:2151-65. 10.1038/s41375-021-01285-3 - DOI - PubMed
    1. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94. 10.1056/NEJM199309303291402 - DOI - PubMed
    1. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61. 10.1182/blood-2006-08-038257 - DOI - PubMed